Change Visitor Type Sign up to our newsletter

Portfolio

Oxford BioTherapeutics

Oxford BioTherapeutics is an oncology drug discovery business. By exploiting its proprietary database of human cell-surface proteins, it creates and develops novel targeted oncology therapeutics, with a focus on Antibody Drug Conjugates and Immune Oncology treatments.

26

    Notice: Undefined variable: feed in /home/oxfordcapital/webapps/oxford-capital-live/wp-content/plugins/oxfordcapital/templates/widget_portfolionews_widget.php on line 78

  • Notice: Undefined variable: feed in /home/oxfordcapital/webapps/oxford-capital-live/wp-content/plugins/oxfordcapital/templates/widget_portfolionews_widget.php on line 78
  • Oxford BioTherapeutics Appoints Chief Medical Officer, ​Abderrahim Fandi


    Read more

  • Notice: Undefined variable: feed in /home/oxfordcapital/webapps/oxford-capital-live/wp-content/plugins/oxfordcapital/templates/widget_portfolionews_widget.php on line 78

  • News and Views

    The lastest industry news and views
    from our team at Oxford Capital.

    see more

  • Notice: Undefined variable: feed in /home/oxfordcapital/webapps/oxford-capital-live/wp-content/plugins/oxfordcapital/templates/widget_portfolionews_widget.php on line 78
  • $1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics


    Read more